|
May 10
|
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Analysts Are Pretty Bullish On The Stock After Recent Results
|
|
May 8
|
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...
|
|
May 7
|
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 7
|
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 2
|
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 30
|
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
|
|
Apr 12
|
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
|
|
Apr 4
|
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
|
|
Mar 12
|
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
|
|
Mar 7
|
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
|
|
Mar 7
|
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
|
|
Mar 6
|
Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),
|
|
Mar 5
|
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
|
|
Mar 5
|
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Jan 15
|
When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?
|
|
Jan 5
|
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
|
Jan 4
|
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
|
|
Jan 3
|
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
|